Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916149 | 0.86 | SLC6A2 (0.38) | KDM4EALDH1A1MAPTHTTSLC6A2 | |
| SCHEMBL27051010 | 0.83 | — | — | |
| SCHEMBL20149146 | 0.81 | ALOX5AP (0.31) | KDM4EMAPT | |
| SCHEMBL22114301 | 0.77 | MAPT (0.38) | KDM4EALDH1A1MAPTHTT | |
| SCHEMBL2558589 | 0.77 | — | — | |
| SCHEMBL30581644 | 0.77 | — | — | |
| SCHEMBL11916153 | 0.76 | RAPGEF4 (0.30) | — | |
| SCHEMBL9945933 | 0.75 | — | — | |
| SCHEMBL10259660 | 0.75 | CA1 (0.31) | — | |
| SCHEMBL8570914 | 0.74 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | RNGTT, RNMT, DNPEP | KDM4E 2520/4885ALDH1A1 2284/4885MAPT 3611/4885 |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | DNPEP, NPEPPS, DHFR | KDM4E 2941/4885ALDH1A1 1379/4885MAPT 1056/4885 |
| US-20120201809-A1 | MULTIFUNCTIONAL ANTIBODY CONJUGATES | CLTB, CLTA, FCGRT | KDM4E 796/4885ALDH1A1 2298/4885MAPT 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.